Literature DB >> 10924986

Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.

M Oguchi1, H Ikeda, K Isobe, S Hirota, M Hasegawa, K Nakamura, K Sasai, N Hayabuchi.   

Abstract

PURPOSE: To identify the prognostic factors that specifically predict survival rates of patients with localized aggressive non-Hodgkin's lymphoma (NHL). METHODS AND MATERIALS: The survey was carried out at 25 radiation oncology institutions in Japan in 1998. The 5-year event-free (EFS) and overall survival rates (OAS) were calculated, and univariate and multivariate analyses were done to identify which of the following factors, namely, gender, age, performance status (PS), serum lactate dehydrogenase (LDH) level, Stage (I vs. II), tumor bulk (maximum diameter), and treatment, were significant from the viewpoint of prognosis.
RESULTS: A total of 1141 patients with Stage I and II NHL were treated by the Japanese Lymphoma Radiation Therapy Group between 1988 and 1992. Of them, 787 patients, who were treated using definitive radiotherapy with or without chemotherapy for intermediate- and high-grade lymphomas in working formulation, constituted the core of this study. Primary tumors arose mainly from extranodal organs (71%) in the head and neck (Waldeyer's ring: 36% and sinonasal cavities: 9%). The factors associated with poorer prognosis were age over 60 years old (p < 0. 0001), radiation therapy alone (p < 0.0001), PS = 2-4 (p = 0.0011), (sex male, p = 0.0078), a bulky tumor more than 6 cm in maximum diameter (p = 0.0088), elevated LDH (p = 0.0117), and stage II (p = 0.0642). A median dose of 42 Gy was delivered mainly to the involved fields. Short-course chemotherapy was provided in 549 (70%) patients. The 5-year OAS and EFS rates for all patients were 71% and 67%, respectively. According to the stage-modified International Prognostic Index, the 5-year EFS of the patients with risk factors from 0 to 1 was 76%, 61% for patients with two risk factors, and 26% for patients with three or more risk factors.
CONCLUSION: Extranodal presentation, especially Waldeyer's ring and sinonasal cavities, is encountered more frequently in Japan than in Western countries. Tumor bulk is an important prognostic factor in patients with localized aggressive extranodal NHL. Short course chemotherapy followed by radiation therapy was associated with prolonged survival in patients with localized aggressive NHLs of extranodal origin and 0-1 risk factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924986     DOI: 10.1016/s0360-3016(00)00480-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature.

Authors:  Nikolaos S Salemis; Stavros Gourgiotis; Evangelos Tsiambas; Grigorios Karagkiouzis; Georgios Nakos; Vasilios Karathanasis
Journal:  J Gastrointest Cancer       Date:  2009

2.  Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy.

Authors:  Agustin Avilés; Natividad Neri; Serafin Delgado; Felipe Pérez; M Jesús Nambo; Sergio Cleto; Alejandra Talavera; Judith Huerta-Guzmán
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Clinical analysis of extranodal non-Hodgkin's lymphoma in the sinonasal tract.

Authors:  J-S Woo; J M Kim; S H Lee; S W Chae; S J Hwang; H-M Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-07-25       Impact factor: 2.503

4.  Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.

Authors:  Xuan Canh Nguyen; Won Woo Lee; Amr Mohamed Amin; Jae Seon Eo; Soo-Mee Bang; Jong Seok Lee; Sang Eun Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

5.  Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation.

Authors:  Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-11-21

6.  Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma.

Authors:  J Spicer; P Smith; K Maclennan; P Hoskin; B Hancock; D Linch; R Pettengell
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.